(Q34017637)

30 July 2017

1 reference

title

Pulmonary delivery of drugs for bone disorders (English)

1 reference

30 July 2017

Patton JS

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

Advanced Drug Delivery Reviews

30 July 2017

published in

1 reference

30 July 2017

volume

42

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

239-248

1 reference

The burden of osteoporosis: cost

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

The economic and human costs of osteoporotic fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Consequences of a hip fracture: a prospective study over 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

The clinical consequences of vertebral compression fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Quality of life issues in women with vertebral fractures due to osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Osteoporosis. Current pharmacologic options for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

The restoration of skeletal mass: A theoretic overview

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Renal Receptors for Calcitonin: Coordinate Occurrence with Calcitonin-Activated Adenylate Cyclase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Calcitonin Receptors of Kidney and Bone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Nasal salmon calcitonin in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Prevention of postmenopausal bone loss by rectal calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Efficacy and safety of drugs for Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Drug delivery via the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Intrapulmonary drug delivery of salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

An evaluation of antibodies and clinical resistance to salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Calcitonin Resistance: Clinical and Immunologic Studies in Subjects with Paget's Disease of Bone Treated with Porcine and Salmon Calcitonins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

The prevention and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Parathyroid hormone binding in vivo to renal, hepatic, and skeletal tissues of the rat using a radioautographic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Effects on Bone In Vitro of Bovine Parathyroid Hormone and Synthetic Fragments Representing Residues 1–34, 2–34 and 3–34

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Breathing life into protein drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

1 reference

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

1 reference

7 January 2021

Safety of inhaled proteins for therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

The dilemma of osteoporosis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900064-8

7 January 2021

10.1016/S0169-409X(00)00064-8

Identifiers

DOI

1 reference

30 July 2017

1 reference